Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01
(varenicline) nasal spray as compared to placebo nasal spray for complete resolution of
corneal staining (0 mm lesion and no residual staining) in subjects with Stage 1 (corneal
epithelial hyperplasia/punctate keratopathy) neurotrophic keratopathy (NK) in one or both
eyes.